Key points from article :
Fujifilm's trial to target patients with acute graft-versus-host disease.
Condition affects about 40% of bone marrow transplant recipients.
Therapy uses induced pluripotent stem (iPS) cells.
Hopes to win approval to manufacture and market the therapy in 2022.
Aims to exploit experience of Australian venture Cynata Therapeutics.
Cynata's UK clinical trials has 14 of 15 patients showing improvement.
Plan to mass-produce mesenchymal stem cells made from iPS cells.
